Plant ID: NPO28778
Plant Latin Name: Eucalyptus viminalis
Taxonomy Genus: Eucalyptus
Taxonomy Family: Myrtaceae
NCBI TaxonomyDB:
155764
Plant-of-the-World-Online:
n.a.
Antiviral; Laxative
Australia; China
FFAR4; FFAR1; | |
CA7; CA4; | |
PPARA; | |
ALOX15; CBR1; AKR1B10; | |
F10; | |
FABP3; LMNA; FABP5; | |
XDH; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | CBR1 | Carbonyl reductase [NADPH] 1 | P16152 | CHEMBL5586 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Serine protease | F10 | Coagulation factor X | P00742 | CHEMBL244 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.104E-10 | 5.126E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 6.912E-11 | 5.126E-07 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, XDH |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.570E-10 | 1.106E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.127E-09 | 5.675E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.622E-09 | 6.891E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 3.245E-08 | 3.533E-05 | AKR1B10, ALOX15, CBR1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, XDH |
BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 6.716E-08 | 6.647E-05 | AKR1B10, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
MF | GO:0005488; binding | GO:0020037; heme binding | 9.445E-08 | 8.569E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.189E-06 | 8.093E-04 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0005488; binding | GO:0005504; fatty acid binding | 1.960E-06 | 1.219E-03 | FABP3, FABP5, FFAR4 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 3.993E-06 | 2.288E-03 | CYP19A1, CYP1A1, CYP2C19 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 4.916E-06 | 2.745E-03 | CYP1A1, CYP1A2 |
BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 5.689E-06 | 3.097E-03 | AKR1B10, CBR1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.228E-05 | 6.520E-03 | CYP1A2, CYP2C19 |
BP | GO:0008152; metabolic process | GO:0044242; cellular lipid catabolic process | 1.724E-05 | 8.731E-03 | AKR1B10, CYP1B1, FABP3, FABP5 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 8.412E-09 | 2.944E-07 | CBR1, CYP1A2, CYP1A1, CYP1B1, CYP2C19 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.890E-07 | 3.307E-06 | CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 4.808E-07 | 5.609E-06 | CBR1, CYP1A2, CYP1A1, CYP1B1 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 5.303E-06 | 3.455E-05 | CBR1, AKR1B10, CYP1A2, ALOX15, CYP1A1, CYP2C19, CYP19A1, XDH |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 5.923E-06 | 3.455E-05 | CYP1A2, CYP1A1, CYP1B1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 2.204E-06 | 1.929E-05 | CYP1A2, ALOX15, CYP2C19 |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.168E-05 | 5.112E-05 | CYP1A1, CYP1B1, CYP19A1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 2.239E-05 | 8.708E-05 | CBR1, ALOX15, CYP2C19 |
09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 3.090E-05 | 1.082E-04 | FABP3, FABP5, PPARA |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.539E-03 | 4.488E-03 | CYP1A2, CYP1A1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.732E-03 | 4.663E-03 | CYP1A2, CYP2C19 |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.032E-04 | 3.284E-04 | CA4, CA7 |
09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 7.638E-06 | 3.819E-05 | CYP1A2, XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hemophilia | D66-D68 | F10; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | F10; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hematology | D50-D77 | F10; |
NA: NA | Haemophilia B | NA | F10; |
I00-I99: Diseases of the circulatory system | Venous thromboembolism | I80-I82 | F10; |
I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | F10; |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; |
I00-I99: Diseases of the circulatory system | Venous thrombosis | I80-I82 | F10; |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
I00-I99: Diseases of the circulatory system | Prophylaxis of deep vein thrombosis | I80-I82, I80.2 | F10; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; |
C00-D49: Neoplasms | Renal cancer | C64 | F10; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | F10; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
NA: NA | Christmas disease | NA | F10; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
I00-I99: Diseases of the circulatory system | Coagulation | I80-I82 | F10; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; |
I00-I99: Diseases of the circulatory system | Deep venous clots | I80.2 | F10; |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | F10; |
I00-I99: Diseases of the circulatory system | Thromboembolic disorders | I80-I82 | F10; |
I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | F10; |
I00-I99: Diseases of the circulatory system | Deep vein thrombosis | I80-I82, I80.2 | F10; |
C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | F10; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | F10; |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | CBR1; |
I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F10; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood coagulation disorders | D65-D68 | F10; |